Case Study: Large Pharma Company uncovers osteoarthritis burden, treatment patterns and economic impact in Dubai with IQVIA Real-World Evidence

Burden, Treatment Patterns and Unmet Needs Of Osteoarthritis In Dubai

Large Pharma company commissioned a retrospective real-world study to quantify the burden, treatment patterns and unmet needs of osteoarthritis in Dubai. The customer worked with IQVIA, leveraging the Dubai Real-World Claims Database (DRWD) and IQVIA Real World Evidence solutions to access de-identified e-claims data from Jan 1, 2014 to May 31, 2020 and support the study design and analysis.

IQVIA provided the DRWD data and analytic support, enabling identification of 11,651 eligible OA patients (3.22% of 361,806 candidates) and generation of key metrics: overall OA incidence 1.7% and prevalence 2.0% (hip/knee incidence 1.2%, prevalence 1.4%), cohort distribution (60% cohort 1; 25% cohort 3; 11% cohort 2; 4% cohort 4), common treatments (oral NSAIDs 41.6%, hyaluronic acid 12.6%, intra‑articular corticosteroids 5.8%) and HCRU/costs (mean inpatient claims 1.4, cost $5,353.30; outpatient claims 24.7, cost $2,840.30). By delivering these real-world insights, IQVIA produced the first Dubai-level estimates of OA epidemiology, treatment and economic burden to inform the Large Pharma company's clinical, HEOR and commercial planning.